Adagio Medical starts strategic review and cuts workforce

Adagio Medical Holdings, Inc. (Nasdaq: ADGM) said on September 23, 2026 that its Board of Directors had completed a comprehensive review of the company's business, programs, resources and capabilities. The board then started a formal process to explore strategic alternatives focused on maximizing shareholder value. The company also said it is implementing a reduction in workforce to align its cost structure with its prioritized programs. The announcement was made in a press release furnished with a Form 8-K that day.

The strategic review

The company said it will explore potential strategic alternatives that may include, but are not limited to, an acquisition, merger, business combination or other transaction. The release states that "There can be no assurance that its exploration will result in Adagio pursuing a transaction." It adds that any transaction, if pursued, may not be completed on attractive terms, if at all.

The company has not set a timetable for the evaluation. It said it does not intend to disclose further developments unless and until it determines that further disclosure is appropriate or necessary. The release does not give the number of positions affected by the workforce reduction, and it does not name any financial advisor engaged for the review.

The company and its programs

Adagio describes itself as a medical device company focused on developing and commercializing products for the treatment of cardiac arrhythmias. Its technology is catheter-based Ultra-Low Temperature Ablation, which the release calls ULTA and says was formerly known as ULTC. The release says the technology is designed to create large lesions that extend through the depth of both diseased and healthy cardiac tissue, all through an endocardial approach.

The company is focused on the treatment of ventricular arrhythmias with its purpose-built vCLAS Ventricular Ablation System, which is CE Marked. The release says Adagio submitted the results of its FULCRUM-VT pivotal study in May 2026 to support a Premarket Approval application to the U.S. Food and Drug Administration. The company is also developing a next-generation vCLAS Ultra catheter, which it says is designed to support faster ablation procedures.

The FULCRUM-VT trial has fully enrolled 209 patients with structural heart disease of both ischemic and non-ischemic cardiomyopathy. The FDA has granted Investigational Device Exemption approval to expand the trial to evaluate the next-generation system for the treatment of Sustained Monomorphic Ventricular Tachycardia. According to the release, the vCLAS Ventricular Tachycardia System is commercially available for monomorphic VT in Europe and select other geographies, but it is limited to investigational use in the United States.

Cash position

The release says that as of June 30, 2026, the company had a preliminary unaudited amount of approximately $7.7 million in cash, cash equivalents and investments in marketable securities. The release does not give a cash runway or any updated operating loss for the period.

The risks ahead

The company has to settle its future with little cash. It reported about $7.7 million in cash, cash equivalents and investments in marketable securities at June 30, 2026, and the filings elsewhere show cash from operations of negative $19.0 million for 2025. The release says there can be no assurance that the review will lead to a transaction, and it set no timetable. The company says it will keep advancing its PMA application for the vCLAS Ventricular Ablation System, but it calls the timing and outcome of the FDA review uncertain. It points readers to the risks in its Form 10-K.

Report an error

Companies in this story

ADGMAdagio Medical Holdings, Inc.NASDAQ · United StatesOpen the starter desk